HRI awarded prestigious Ramaciotti grant

Awards and Achievements
Dr Sanjay Patel, Group Leader at the Heart Research Institute, has been awarded a highly prestigious Ramaciotti Grant to pursue his work developing a cost-effective therapy to prevent heart attack and stroke.

The five Ramaciotti Health Investment Grants of $150,000 are awarded to autonomous early career scientists to support health or medical research with a potential path to clinical application within five years.

The grant will allow Dr Patel to pursue his work developing a novel cost-effective therapy to stop the progression of atherosclerosis before it leads to heart attack and stroke.

This project targets inflammation, by testing the cardio-protective properties of colchicine, a widely available and cost-effective anti-inflammatory drug that has long been used to treat arthritis caused by gout.

Dr Patel, who is also an interventional cardiologist at Royal Prince Alfred Hospital Hospital, discovered that colchicine, can significantly improve heart health by lowering the levels of dangerous inflammatory proteins.

Inflammatory cells and proteins play a critical role in atherosclerosis, fat build-up in the vessel wall, the leading cause of death and disability in Australia. Despite current best treatments, many people remain at high risk of cardiovascular complications such as stroke, or heart attack – which claims the life of someone in Australia every 24 minutes.

"If we're able to prove its success in larger studies, we'll have a brand new therapy that will considerably brighten the outlook for people who suffer heart attacks," said Dr Patel

In initial studies, Dr Patel studied 40 people with acute coronary syndrome, a life-threatening condition in which the coronary blood vessel is blocked, causing heart attack or severe chest pain.

“In these studies we are able to treat patients straight away, and have already in preliminary research,” he said.

“It is highly likely that successful studies will lead to colchicine becoming a clinical treatment for atherosclerosis within the next five years, decreasing the risk of heart attack and stroke for more than 230,000 people in Australia with atherosclerosis.”

Patients who have the condition have plaques on their arteries causing the blockages, and often have high levels of some inflammatory markers, known as Interleukins β, 18 and 6, in their blood.

"We know from pathology and histology that when you take coronary arteries from patients who have died, the plaques are just full of inflammatory markers and proteins," he said.

"Inflammation is really intimately involved with every stage of the disease."

The Ramaciotti Foundation is one of the biggest and most prestigious philanthropic contributors to medical research in Australia, awarding just five Health Investment Grants each year. Previous Ramaciotti winners having been responsible for the development of the world’s first cervical cancer vaccines and the Cochlear implant, highlighting the significant impact that philanthropy can have on the wellbeing of millions of people.

Husband and wife team Professor Jane Visvader and Professor Geoff Lindeman, of the Walter and Eliza Hall Institute of Medical Research, were selected as the joint recipients of the Ramaciotti Medal for Excellence in Biomedical Research, an annual award of $50,000 to honour an outstanding discovery in clinical or experimental biomedical research.  Professors Visvader and Lindeman received the medal for their pioneering work in discovering new approaches to breast cancer treatment and prevention.

Perpetual is a trustee of the Clive and Vera Ramaciotti Foundation.

Congratulations to all the Ramaciotti Health Investment Grants recipients!


Project Title

Dr Jane Kohlhoff


The ‘Watch Me Grow’ App for identification of developmental and mental health problems in early childhood: a validation study

A/Professor Lyndell Lim Centre for Eye Research Australia Improving cataract surgery outcomes in patients with Diabetic Macular Oedema (the DiMeCAT Trial)
A/Professor Philippa Middleton

South Australian Health and Medical Research Institute Ltd

Optimega: Preventing preterm birth and improving long term and intergenerational health through personalising dietary fat intake for pregnant women

Dr Sanjay Patel The Heart Research Institute

Colchicine – A novel role in stabilising vulnerable atherosclerotic plaque

Dr Mark Polizzotto

UNSW Australia (Kirby Institute for Infection and Immunity)

Immune modulation for prevention of anogenital cancer in people with persistent high-grade anal intraepithelial neoplasia



Related news

Sydney Cardiovascular Fellowships 2018 now open

The Heart Research Institute and the Charles Perkins Centre of the University of Sydney are seeking exceptional national and international early to mid-career researchers with the potential to become global leaders in cardiovascular research for the Sydney Cardiovascular Fellowships 2018.

Read more

New drug hope to target silent killer

An exciting new treatment for very high blood pressure is on the horizon after a world-first discovery by Heart Research Institute scientists, who have uncovered a brain chemical instrumental in triggering hypertension, the so-called silent killer responsible for the deaths of thousands of Australians each year.

The researchers are optimistic the results, published this week in the American Journal of Physiology-Heart and Circulatory Physiology, will ultimately lead to a powerful new treatment that blocks a neurotransmitter and frees patients from the dangers of hypertension. 

Read more

Gout drug mends broken hearts

A drug used to treat arthritis has been found to clear clogged arteries in heart attack survivors, world-first Australian research shows.

The landmark discovery by Associate Professor Sanjay Patel, Leader of the Cell Therapeutics Group, and his team at the HRI paves the way for a cheap, simple and effective treatment regime that could protect thousands of Australian heart patients from future attacks that might kill them or further damage their heart. 

Read more